XOOMAR

VERTEX PHARMACEUTICALS INC / MA (VRTX)

Every FINRA and SEC series the site collects for VERTEX PHARMACEUTICALS INC / MA: short interest with days to cover, daily short sale volume, fails to deliver and Form 4 insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.

Download CSV

4.1M

Short interest

settlement 2026-08-14

3.1

Days to cover

+5.2% vs prior

63.0%

Short share of volume

2026-09-11

255

Fails to deliver

settlement 2026-08-05

-$759K

Insider flow, 90 days

0 buys, 2 sells

As of 2026-09-11.

Short interest

FINRA, twice a month; the last 12 months shown, all 48 settlements in the JSON

As of 14 August 2026, short interest in VRTX is 4,146,973 shares, down 839,718 shares over the last month. Over the last 48 readings it ranged from 3,512,605 shares (13 December 2024) to 5,753,349 shares (14 March 2025). At the reported average volume of 1.3M shares a day that is 3.1 days to cover.

Embed this chartfree, with the attribution line it carries
<iframe src="https://xoomar.com/embed/stocks/vrtx" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
PreviewDark previewAdd ?theme=dark to the src for a dark chart.
SettlementShares shortChangeAvg daily volumeDays to cover
2026-08-144,146,973+5.2%1,343,9083.09
2026-07-313,942,936-20.9%1,318,0612.99
2026-07-154,986,691+1.0%1,607,8173.10
2026-06-304,938,472+7.0%2,454,8492.01
2026-06-154,616,968+2.8%1,209,8553.82
2026-05-294,491,490+0.7%1,406,7843.19
2026-05-154,461,773+6.9%1,224,8733.64
2026-04-304,172,829-3.8%967,5904.31
2026-04-154,336,502+7.8%1,147,8003.78
2026-03-314,021,854-2.6%1,493,4842.69
2026-03-134,127,429-6.9%1,448,6252.85
2026-02-274,433,365-0.7%1,262,6923.51
2026-02-134,466,182+1.0%1,676,3212.66
2026-01-304,422,490-0.0%1,586,4052.79
2026-01-154,423,965-11.9%1,437,3723.08
2025-12-315,022,282+17.1%1,227,5944.09
2025-12-154,287,121-3.8%1,361,3173.15
2025-11-284,455,217+11.2%1,393,8143.20
2025-11-144,006,159-3.0%1,492,4622.68
2025-10-314,131,677+16.2%1,281,3663.22
2025-10-153,555,766-0.0%1,343,8662.65
2025-09-303,557,058-12.3%2,027,1321.75
2025-09-154,053,668+11.4%1,277,9243.17
2025-08-293,639,292-1.7%1,570,2842.32

Daily short volume

FINRA Reg SHO, last 60 sessions. JSON

As of 11 September 2026, the short share of VRTX volume is 63.0%, down 6.3 points over the last five sessions. Over the last 52 readings it ranged from 20.5% (28 July 2026) to 71.2% (25 August 2026). The latest reading is 5.4 points above the 30-session average of 57.6%, on 229K shares reported.

DateShort volumeTotal volumeShort shareExempt
2026-09-11144K229K63.0%0
2026-09-10143K233K61.3%20
2026-09-09153K285K53.8%6
2026-09-08195K303K64.4%267
2026-09-04171K276K61.9%0
2026-09-03170K246K69.3%1,368
2026-09-02484K857K56.4%85
2026-09-01159K272K58.6%1,140
2026-08-31168K244K68.8%3
2026-08-28160K249K64.2%76
2026-08-27246K385K63.8%74
2026-08-26188K276K68.2%49
2026-08-25174K245K71.2%298
2026-08-24138K210K65.7%0
2026-08-21207K338K61.1%1,730
2026-08-20159K294K54.1%140
2026-08-19337K538K62.6%400
2026-08-18355K499K71.2%38
2026-08-17208K418K49.6%6
2026-08-14134K248K54.1%109
2026-08-13176K313K56.3%127
2026-08-12215K355K60.5%379
2026-08-11211K372K56.7%2,170
2026-08-10683K1.1M62.1%723
2026-08-07124K305K40.8%171
2026-08-06122K353K34.5%8,115
2026-08-05167K353K47.3%2,122
2026-08-04282K595K47.5%24
2026-08-03162K446K36.4%294
2026-07-31118K282K42.0%192

Fails to deliver

SEC, by settlement date. JSON

As of 5 August 2026, the fails-to-deliver balance in VRTX is 255 shares, down 353 shares over the last settlement date. Over the last 52 readings it ranged from 1 share (2 December 2025) to 44,303 shares (1 July 2026). The latest reading sits at the bottom of that range.

SettlementShares failedPriceValue
2026-08-05255$478.71$122K
2026-07-28608$479.00$291K
2026-07-223,256$482.00$1.6M
2026-07-17102$486.03$50K
2026-07-1618$477.08$9K
2026-07-06500$528.04$264K
2026-07-0144,303$496.73$22.0M
2026-06-2924$491.34$12K
2026-06-253,775$475.20$1.8M
2026-06-153,554$444.93$1.6M
2026-06-121,170$445.04$521K
2026-06-091$442.96$443
2026-06-0847$446.83$21K
2026-06-02601$438.40$263K
2026-04-241,290$435.10$561K
2026-04-231$437.67$438
2026-04-162,143$441.70$947K
2026-04-1514$444.28$6K
2026-04-081$431.86$432
2026-03-3042,186$433.07$18.3M
2026-03-255,705$448.62$2.6M
2026-03-232,095$454.00$951K
2026-03-1740,515$466.10$18.9M
2026-03-13341$478.13$163K
2026-02-25300$487.43$146K
2026-02-24300$481.01$144K
2026-02-201,216$469.27$571K
2026-02-1872$477.32$34K
2026-02-1714,013$491.47$6.9M
2026-02-13300$465.02$140K

Insider trades

SEC Form 4, newest first, 50 of 100 shown. JSON

Insiders at VRTX reported 2 open-market sells worth $759K in the last 90 days and no open-market buys. Sells alone are a weak signal; insiders sell for tax, diversification and estate reasons all the time. Latest filing: Ambrose Kristen (SVP &amp; Chief Accounting Officer) on 2026-08-28.

DateInsiderTitleTypeSharesPriceValueOwned after
2026-08-28Ambrose KristenSVP &amp; Chief Accounting OfficerGrant5K$0.00$012K
2026-08-27SACHS BRUCE In/aGift6K$0.00$039K
2026-06-26Bozic CarmenEVP and CMOSell596$482.50$288K15K
2026-06-18Bozic CarmenEVP and CMOSell1K$462.17$471K16K
2026-06-05Bozic CarmenEVP and CMOSell2K$450.00$785K21K
2026-06-01Liu JoyEVP and Chief Legal OfficerSell828$439.91$364K20K
2026-05-29Bozic CarmenEVP and CMOSell2K$450.00$888K23K
2026-05-15Bunnage Mark E.EVP, Chief Scientific OfficerSell33$453.45$15K7K
2026-05-15Bozic CarmenEVP and CMOSell1K$453.45$614K25K
2026-05-12Bozic CarmenEVP and CMOSell7K$450.00$3.1M26K
2026-05-04Bhatia Sangeeta N.n/aSell318$423.73$135K5K
2026-05-01Thornberry Nancyn/aGrant472$0.00$03K
2026-05-01Schneider Jennifern/aGrant472$0.00$02K
2026-05-01MCKENZIE DIANAn/aGrant943$0.00$03K
2026-05-01Liu JoyEVP and Chief Legal OfficerSell1K$425.02$469K21K
2026-05-01Garber Alan Mn/aGrant472$0.00$07K
2026-05-01Bhatia Sangeeta N.n/aGrant943$0.00$05K
2026-04-01Liu JoyEVP and Chief Legal OfficerSell978$449.17$439K22K
2026-03-27Bozic CarmenEVP and CMOSell2K$450.95$1.1M33K
2026-03-13Bozic CarmenEVP and CMOSell2K$481.79$1.1M35K
2026-03-11McKechnie DuncanEVP, Chief Commercial OfficerSell3K$498.42$1.3M12K
2026-03-04McKechnie DuncanEVP, Chief Commercial OfficerSell2K$475.30$1.2M15K
2026-03-02Liu JoyEVP and Chief Legal OfficerSell892$495.96$442K23K
2026-02-27Kewalramani ReshmaCEO &amp; PresidentSell2K$496.95$857K98K
2026-02-27Kewalramani ReshmaCEO &amp; PresidentSell6K$496.16$3.0M100K
2026-02-27Kewalramani ReshmaCEO &amp; PresidentSell16K$495.38$7.7M106K
2026-02-27Kewalramani ReshmaCEO &amp; PresidentSell3K$494.33$1.7M122K
2026-02-27Kewalramani ReshmaCEO &amp; PresidentSell3K$493.29$1.2M125K
2026-02-27Kewalramani ReshmaCEO &amp; PresidentSell949$491.30$466K128K
2026-02-27Kewalramani ReshmaCEO &amp; PresidentSell3K$490.54$1.3M129K
2026-02-27Kewalramani ReshmaCEO &amp; PresidentSell460$489.32$225K131K
2026-02-27Kewalramani ReshmaCEO &amp; PresidentSell3K$488.27$1.6M132K
2026-02-27Kewalramani ReshmaCEO &amp; PresidentSell3K$487.13$1.2M135K
2026-02-27Kewalramani ReshmaCEO &amp; PresidentSell240$482.84$116K138K
2026-02-27Kewalramani ReshmaCEO &amp; PresidentSell120$481.50$58K138K
2026-02-27Kewalramani ReshmaCEO &amp; PresidentSell400$479.75$192K138K
2026-02-27Bozic CarmenEVP and CMOSell2K$480.31$1.1M38K
2026-02-26Ambrose KristenSVP &amp; Chief Accounting OfficerSell357$483.36$173K7K
2026-02-25Tatsis OuraniaEVP, Chief Reg. &amp; Quality Off.Sell260$486.35$126K47K
2026-02-25Sachdev AmitEVP Chief Patient &amp; Ext Af OffSell2K$486.35$898K56K
2026-02-25McKechnie DuncanEVP, Chief Commercial OfficerSell2K$489.00$1.2M18K
2026-02-25McKechnie DuncanEVP, Chief Commercial OfficerSell3K$486.35$1.2M20K
2026-02-25Bunnage Mark E.EVP, Chief Scientific OfficerSell620$486.35$302K7K
2026-02-25Biller JonathanEVP and Chief Legal OfficerSell945$486.35$460K14K
2026-02-25Atkinson Edward Morrow IIIEVP, Chief Technical Ops. Off.Sell668$486.35$325K18K
2026-02-25Ambrose KristenSVP &amp; Chief Accounting OfficerSell223$486.35$108K7K
2026-02-24WAGNER CHARLES F JREVP, CO &amp; FOTax withholding2K$485.11$846K47K
2026-02-24Tatsis OuraniaEVP, Chief Reg. &amp; Quality Off.Tax withholding2K$485.11$789K47K
2026-02-24Sachdev AmitEVP Chief Patient &amp; Ext Af OffTax withholding2K$485.11$736K57K
2026-02-24McKechnie DuncanEVP, Chief Commercial OfficerTax withholding873$485.11$424K22K

Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are the rarer, stronger signal.

13F holders

Tracked managers holding VRTX at their latest 13F. JSON

9 of the 30 tracked managers held VRTX at their latest 13F, $1.36B in total at quarter-end prices. Citadel Advisors is the largest at $441.9M (0.1% of its portfolio) as of 2026-06-30. Over the prior quarter 3 added shares and 6 cut.

FundQuarterSharesValueOf portfolioChange in shares
Citadel Advisors2026-06-30890K$441.9M0.05%+258K
AQR Capital Management2026-06-30616K$305.0M0.11%+445K
Millennium Management2026-06-30564K$280.1M0.10%+381K
Renaissance Technologies2026-06-30320K$159.0M0.22%-102K
Two Sigma Investments2026-06-30287K$142.8M0.10%-92K
Fisher Asset Management2026-06-3024K$12.2M0.00%-7K
Point72 Asset Management2026-06-3019K$9.3M0.01%-2K
D. E. Shaw & Co.2026-06-3018K$9.0M0.00%-231K
Bridgewater Associates2026-06-3011K$5.4M0.02%-2K

Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.

Financials

SEC XBRL, as filed. JSON

In Q2 2026 (quarter ended 2026-06-30) VERTEX PHARMACEUTICALS INC / MA reported revenue of $3.33B, up 12.5% from the same quarter a year earlier, and net income of $1.10B (4.31 diluted EPS). In FY 2025 it generated $3.63B of operating cash flow and spent $2.02B on buybacks.

Cash
$6.14B
Equity
$20.25B
Total assets
$27.42B
Shares outstanding
253,460,924

Quarterly, last 8 quarters

QuarterPeriod endRevenueNet incomeMarginDiluted EPS
Q2 20262026-06-30$3.33B$1.10B33.0%4.31
Q1 20262026-03-31$2.99B$1.03B34.5%4.02
Q4 2025derived2025-12-31$3.19B$1.19B37.3%n/a
Q3 20252025-09-30$3.08B$1.08B35.2%4.20
Q2 20252025-06-30$2.96B$1.03B34.8%3.99
Q1 20252025-03-31$2.77B$646.3M23.3%2.49
Q4 2024derived2024-12-31$2.91B$913.0M31.4%n/a
Q3 20242024-09-30$2.77B$1.05B37.7%4.01

Fiscal years, with buybacks and dividends

Fiscal yearEndsRevenueNet incomeOperating cash flowCapexBuybacksDividends
FY 20252025-12-31$12.00B$3.95B$3.63B$437.6M$2.02Bn/a
FY 20242024-12-31$11.02B-$535.6M-$492.6M$297.7M$1.18Bn/a
FY 20232023-12-31$9.87B$3.62B$3.54B$200.4M$427.6Mn/a
FY 20222022-12-31$8.93B$3.32B$4.13B$204.7M$0n/a
FY 20212021-12-31$7.57B$2.34B$2.64B$235.0M$1.43Bn/a

Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are cash paid to repurchase common stock in the year (XBRL PaymentsForRepurchaseOfCommonStock), not authorizations. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-07-31 from the cover page.

What this page is

VERTEX PHARMACEUTICALS INC / MA in the regulatory record

Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page pulls every series the site collects for one ticker onto one URL, keyed by the SEC's own ticker list, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.

Each section has its own history table, a summary sentence built from the rows (last value, change, range with dates) and its own JSON and CSV links. Nothing on the page is written by a model; the sentences change only when the data does. A page exists only for companies with data in at least two series, and every section says when its source last updated.

This page follows VERTEX PHARMACEUTICALS INC / MA (VRTX), SEC CIK 875320, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.

Source and method

Short interest
FINRA consolidated short interestTwice a month, about eight business days after settlement. Latest 2026-08-14.JSON and CSV
Daily short volume
FINRA Reg SHO daily filesEvery trading day, loaded the following morning. Latest 2026-09-11.JSON and CSV
Fails to deliver
SEC fails-to-deliver dataTwice a month, a few weeks after the half month ends. Latest 2026-08-05.JSON and CSV
13F holders
SEC EDGAR Form 13F-HRQuarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
Financials
SEC XBRL company factsRefreshed weekly from the SEC's structured data; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
Insider trades
SEC EDGAR Form 4EDGAR read every 30 minutes; filings are due two business days after the trade. Latest 2026-08-28.JSON and CSV
Company record
EDGAR filing index for CIK 875320Ticker, name and exchange from the SEC's company list, refreshed weekly.
Rate limits
30 requests a minute without a key, 120 a minute with a key from a free account.

Data checks. Every dataset is checked against its source once a day. This dataset passed the last run, 13 Sep 05:40 UTC.

How to read it

  • Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
  • Insider buys next to a crowded short are the combination that has historically preceded squeezes; insider sells next to a crowded short are common and mean little.
  • Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.

Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.

Other companies the SEC classifies as pharmaceutical preparations

Datasets

Frequently Asked Questions

How much of VRTX is sold short?
4,146,973 shares were held short at the 2026-08-14 settlement, 3.1 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is VRTX's daily short volume?
On 2026-09-11, 144,280 of the 229,006 VRTX shares reported to FINRA were sold short, 63.0% of the day's reported volume. Short volume is a flow for one day, not a position.
Does VRTX have fails to deliver?
The SEC's latest file shows 255 VRTX shares failed to deliver at settlement 2026-08-05. Fails are reported per settlement date and published twice a month with a lag.
Are VRTX insiders buying or selling?
Insiders at VRTX reported 2 open-market sells worth $759K in the last 90 days and no open-market buys. Sells alone are a weak signal; insiders sell for tax, diversification and estate reasons all the time. Latest filing: Ambrose Kristen (SVP &amp; Chief Accounting Officer) on 2026-08-28.
What did VRTX report last quarter?
In Q2 2026 (quarter ended 2026-06-30) VERTEX PHARMACEUTICALS INC / MA reported revenue of $3.33B, up 12.5% from the same quarter a year earlier, and net income of $1.10B (4.31 diluted EPS). In FY 2025 it generated $3.63B of operating cash flow and spent $2.02B on buybacks.
Which funds hold VRTX?
9 of the 30 tracked managers held VRTX at their latest 13F, $1.36B in total at quarter-end prices. Citadel Advisors is the largest at $441.9M (0.1% of its portfolio) as of 2026-06-30. Over the prior quarter 3 added shares and 6 cut.

Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.